What is it about?
This is about special cells in our body called Regulatory T cells (let's call them "peacekeepers"). These cells help keep our immune system in check and stop it from attacking our own body. In people with rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA), there aren't enough of these peacekeepers, or they're not working well.
Featured Image
Photo by National Institute of Allergy and Infectious Diseases on Unsplash
Why is it important?
Understanding these peacekeeper cells is really important because: When there aren't enough peacekeepers, the body's immune system goes into overdrive This causes inflammation and damages joints in people with RA and JIA If we can boost the number or improve how these peacekeepers work, we might be able to help people with these types of arthritis
Perspectives
Scientists have been studying these peacekeeper cells a lot, and here's what they've found: People with RA and JIA don't have enough peacekeepers, and the ones they do have aren't working great This lack of peacekeepers is part of what causes these types of arthritis Researchers think that if we can increase the number of peacekeepers or help them work better, we could treat RA and JIA more effectively They're looking at different ways to do this, like giving patients special proteins that encourage more peacekeepers to grow, or even taking peacekeepers out of the body, growing more of them, and putting them back in This research is exciting because it's looking at treating arthritis in a whole new way. Instead of just trying to reduce pain or inflammation, it's about fixing the underlying problem in the immune system. It's like training more peacekeepers to keep the body's defenses in line and stop them from attacking the joints. This could lead to better treatments for people suffering from these painful conditions.
Prof Louis Tong
National University of Singapore
Read the Original
This page is a summary of: Role of regulatory T cells in pathogenesis and therapeutics of rheumatoid arthritis and juvenile idiopathic arthritis, January 2024, Elsevier,
DOI: 10.1016/b978-0-443-13947-5.00019-1.
You can read the full text:
Contributors
The following have contributed to this page
